Red blood cell transfusion and outcome in cancer

Nayyer Iqbal, Kamal Haider, Vinita Sundaram, Julia Radosevic, Thierry Burnouf, Jerard Seghatchian, Hadi Goubran

研究成果: 雜誌貢獻回顧型文獻

2 引文 斯高帕斯(Scopus)

摘要

Oncology services utilize about 15% of the blood transfusion resources in the USA. Red blood cell transfusion is performed immediately before, during or after major surgery to compensate for blood loss and hemodilution. However, a lack of evidence-based guidelines leads to variable transfusion practices among clinicians. The benefits of transfusing blood products are obvious in life-threatening low blood cell counts or bleeding, but it is becoming apparent that deliberate blood transfusion in some cancer patients can trigger negative clinical impacts. This review attempts to provide an overview of the impact of red blood cell transfusion in patients suffering from various types of oncologic pathologies.
原文英語
頁(從 - 到)287-290
頁數4
期刊Transfusion and Apheresis Science
56
發行號3
DOIs
出版狀態已發佈 - 六月 1 2017

    指紋

ASJC Scopus subject areas

  • Hematology

引用此

Iqbal, N., Haider, K., Sundaram, V., Radosevic, J., Burnouf, T., Seghatchian, J., & Goubran, H. (2017). Red blood cell transfusion and outcome in cancer. Transfusion and Apheresis Science, 56(3), 287-290. https://doi.org/10.1016/j.transci.2017.05.014